Table 3 Maximum and minimal overlapping regions in recurrent chromosome aberrations with tumor related genes located in the minimal overlapping regions.
From: Molecular and clinicopathologic characterization of intravenous leiomyomatosis
Maximum interval (kb) | Minimum interval (kb) | Relevant genes | Number of cases (%) | |
|---|---|---|---|---|
1p36.33p11.2: 564,424-121,322,377 (120,758) | 1p35.2p33: 30,665,772-46,928,430 (16,263) | LCK, SFPQ, THRAP3, CSF3R, MYCL, MPL, MUTYH, MEAF6 | 8 (29%) | 11 (39%) |
1p22.3p13.3: 85,239,163-111,475,662 (26,236) | BCL10, RPL5, TGFBR3, RBM15 | 9 (32%) | ||
1p13.2p13.1: 111,967,027- 116,618,073 (4,651) | TRIM33, NRAS | 9 (32%) | ||
1q21.1q44: 143,787,504-247,139,492 (103,352) | 1q31.2q32.1: 201,586,748-202,001,197 (414) | ELF3, FH | 7 (25%) | |
2q11.1q37.3: 95,529,039-243,028,452 (147,499) | 2q12.2q21.1: 106,120,724-130,333,677 (24,213) | RGPD3, RANBP2, PAX8, ERCC3 | 5 (18%) | 8 (29%) |
2q31: 176,959,166-177,055,486 (96) | HOXD13, HOXD11 | 7 (25%) | ||
2q37.3: 240,116,052-240,320,953 (205) | – | 5 (18%) | ||
3q11.1q29: 93,575,285-198,154,829 (104,580) | 3q21.1q24: 123,390,999-146,012,579 (22,622) | GATA2, RPN1, CNBP, STAG1, PIK3CB, FOXL2, ATR | 4 (14%) | 5 (18%) |
3q13.3q21.1: 121,295,144-123,300,941 (2,006) | – | 4 (14%) | ||
5q11.2q35.3: 54,636,411-180,598,584 (125,962) | 5q33.3q34: 157,708,829-165,950,962 (8,242) | EBF1, PWWP2A | 4 (14%) | |
6q11.1q25.1: 62,448,434-151,805,950 (89,358) | 6q14.3q16.1: 87,044,032-95,997,166 (8,953) | EPHA7 | 3 (11%) | 4 (14%) |
6q16.1q16.3: 97,695,181-99,998,194 (2,303) | – | 3 (11%) | ||
8p23.2p11.1: 2,308,926-43,452,795 (41,144) | 8p23.2: 2,308,926-2,965,283 (656) | – | 1 (4%) | 4 (14%) |
8p23.1p11.21: 9,615,685-43,167,985 (33,552) | LEPROTL1, WRN, NRG1, NSD3, ANK1, KAT6A, IKBKB, HOOK3 | 3 (11%) | ||
8q11.21q24.3: 50,336,903-145,976,051 (95,639) | 8q12.1q24.3: 56,899,737-142,274,992 (85,375) | PLAG1, CHCHD7, PREX2, NCOA2, HEY1, CNBD1, NBN, RUNX1T1, CDH17, COX6C, PABPC1, UBR5, RSPO2, EIF3E, CSMD3, RAD21, EXT1, MYC, NDRG1, FAM135B | 3 (11%) | 4 (14%) |
10q11.21q26.3: 42,209,250-135,254,513 (93,045) | 10q22.2q26.3: 76,458,215-133,476,839 (57,019) | KAT6B, GATA3, NUTM2B, LARP4B, BMPR1A, NUTM2D, FAM22B, PTEN, FAS, TLX1, NFKB2, SUFU, NT5C2, VTI1A, TCF7L2, SHTN1, FGFR2, CPEB3, CYP2C8, MGMT, MGEA5 | 5 (18%) | |
13q11q34: 18,194,544-112,732,368 (94,538) | 13q14.2q14.3: 47,559,566-52,307,072 (4,748) | RB1, CYSLTR2 | 5 (18%) | 6 (21%) |
13q21.2q21.33: 62,222,639-72,463,336 (10,241) | – | 5 (18%) | ||
13q22.3q34: 77,509,972-112,586,620 (35,077) | GPC5, SOX21, ERCC5 | 4 (14%) | ||
14q11.2q32.33: 19,323,579-105,432,573 (86,109) | 14q12q22.1: 27,867,557-51,125,450 (23,258) | ARHGAP5, BAZ1A, NKX2-1, FOXA1 | 5 (18%) | 6 (21%) |
14q24.1q24.2: 68,603,041-69,446,436 (843) | RAD51B | 5 (18%) | ||
22q11.1q13.33: 15,533,988-51,219,009 (35,685) | 22q12.1q12.3: 25,351,942-31,211,236 (5,859) | MN1, CHEK2, ZNRF3, EWSR1, NF2, SMARCB1, DEPDC5 | 9 (32%) | 10 (36%) |
22q13.1q13.33: 36,788,138- 48,390,822 (11,603) | ZC3H7B, APOBEC3B, PDGFB, MRTFA, EP300 | 9 (32%) | ||
22q12.3q13.1: 37,300,872- 37,976,764 (676) | – | 9 (32%) | ||
